ft-002
Gene therapyexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2023 (NCT05874310)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- X-linked retinitis pigmentosa GTPase regulatorSupplementation
supplementation - rpgr
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06492850 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2024 | Chinese Academy of Medical Sciences, Frontera Therapeutics |
| NCT05874310 | Early Phase 1 (Phase 1) | Feb 1, 2023 | Chinese Academy of Medical Sciences, Frontera Therapeutics, Fudan University, Henan Provincal People's Hospital |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chinese Academy of Medical Sciences | Academic/Hospital | 2 | 0 | 2 | 2023 |
| Frontera Therapeutics | For profit | 2 | 2 | 2 | 2023 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Henan Provincal People's Hospital | Academic/Hospital | 1 | 0 | 1 | 2023 |
4 organizations
Page 1 / 1